边锋游戏大厅进不去| 全民彩票手机版| 苹果手机棋牌游戏换现金| 游戏茶苑边锋集团| 捕鱼提现到支付宝| 多盈彩票登录| 北京pk10彩票官网下载| 电玩捕鱼美人鱼| 彩计划app| 世界杯彩票投注网站| 微信注册捕鱼送分| 水果老虎机游戏手机版下载安装| 注册送18元的彩票App| 星力捕鱼平台客服| 新万博客户端| 优博平台| 娱乐棋牌室| 欢乐牛牛腾讯官方下载| 贝贝棋牌游戏中心官方| 吉祥棋牌客户端下载| 手机版可提现的水果机| 新凤凰彩票平台| 疯狂老虎机游戏下载| 欢乐棋牌游戏大厅| 联众天天斗地主单机版下载| 新开手机棋牌游戏平台| 新濠天地官网| 外围角球滚球技巧| 035棋牌游戏官网| 500万彩票网彩民论坛| 足球即时比分 310直播| 98彩票网手机客户端| 联众世界大厅下载安装| 平台娱乐| 星力旗下捕鱼平台| 游戏茶苑乐清麻将| 语文游戏| 快乐彩票的网址| 联众棋牌象棋| 千赢app| 2018捕鱼平台可提现| 中国移动游戏大厅下载| 华夏娱乐彩票平台| 福利彩票pk10投注站| 快乐牛牛游戏| 东升彩票在线| 威尼斯官方网投| 亲朋手机短信充值官网| 中国体育彩票app| 体育竞猜世界杯| 联众世界游戏大厅注册| 赛马资讯香港赛马| 金蟾捕鱼平台| 035棋牌官网登录| cke体育娱乐公司| 篮球滚球| 三公怎么玩才能赢钱| 聚信娱乐平台下载| 体育竞猜keno| 娱网棋牌大连穷胡| 拉菲彩票官网| 波克棋牌| 北京pc28开奖结果| 310足球预测| 星空棋牌大厅下载手机版| k8彩票手机客户端| 打麻将开挂| 悦博体育| 真人德扑圈新手怎么玩| 万博体育| 2018中国象棋个人赛| 创世彩票最新手机版下载| 四季彩票平台| 波克城市手机版大厅| 鸿运国际娱乐| 老虎机安卓版| 乐彩注册| jj斗地主官方网站| 支付宝彩票最大奖| 大富豪棋牌游戏代理| 中国象棋游戏大厅下载| 棋牌娱乐游戏城| 边锋麻将下载手机版| 99电玩官方下载| 游戏茶苑牛牛辅助器| 好乐棋牌官网| pt游戏手机打法技巧| 彩票在线| 茶苑斗牛银子官方版| 苹果机游戏单机| 古怪猴子怎么找规律| 联众德州扑克下载| 百人牛牛下载| 东方彩票平台注册| 彩票论坛交流| 2016棋牌游戏送现金| 广东快乐十分官方网| 99捕鱼| 边峰双扣免费下载| jj四人斗地主| 99彩票娱乐平台网址| 百人牛牛游戏| 茶苑斗牛| 彩票pk10计划软件下载| 网上K彩彩票投注平台| 波克捕鱼| 全天pk10计划精准版| 亅亅斗地主电脑版下载| 365天天彩票网站| 优德娱乐| 亲朋棋牌官网下载| 波克城市电话费充值卡| 真人捕鱼赢钱| 老虎游戏中心| 游戏茶苑2009官方网站| 好友彩票| 快赢彩票app| 5oo万彩票网| 娱网棋牌游戏下载安装| 疯狂老虎机| 黑桃k彩票娱乐| 线上购买彩票| 联众世界游戏大厅| 卡牌游戏推荐| 捕鱼达人千炮版弹头| 易赢娱乐注册| 亲朋棋牌游戏官方网站| 怎样投注才能赢到钱| v10娱乐彩票| 58彩票网| 老虎机怎么打才能赢| 天天斗地主(联众)| ag真人视讯app| 微信提现万人水果机| 现金电玩捕鱼注册送分| 百人牛牛捕鱼游戏中心| 波克城市波克斗地主| 500彩票娱乐有人玩| 优信彩票最高邀请码| 中国体育彩票软件下载| 中国游戏中心棋牌手机版下载| 合法的体育投注平台| 开户绑定手机领体验金| 正规手机彩票投注| jj斗地主金币怎么交易| 边锋斗地主游戏大厅| 宝盈娱乐| 大赢家足球| 夺宝捕鱼游戏官网| 微信棋牌代理| 亲朋游戏中心官方登录| 波克城市账号找回| 老虎机游戏单机版下载| 棋牌捕鱼评测网大全| 88必发娱乐开户| 支付宝双色球彩票| 手机棋牌| 联众大厅官方下载安装| 联众棋牌手机版下载| 优博平台注册| 万博体育官方下载| 上下分的斗地主游戏| 电玩捕鱼城| 乐58彩票| 大发体育娱乐城备用网| 快乐炸金花小游戏| 10元提现棋牌游戏| 常州游戏茶苑下载| 德扑圈最新官网安卓| 波克棋牌游戏| 波克城市棋牌大厅下载| 万博彩票下载| 乐彩彩票网址| 亚洲信誉彩票平台网| 千赢国际手机登录| 滚球对冲技巧| 捕鱼王捕鱼| 幸运彩票平台| 波克棋牌手机官网| 元游象棋游戏大厅| 口袋德扑安卓下载| 商都茶苑棋牌| 常州游戏茶苑| 百灵百人牛牛| 千禧棋牌| 龙虎黄金线| 足球彩票投注| 博猫彩票app客户端| 万博体育资讯| 在线二十一点手机游戏| 90足球比分网即时比分| 188体育直播吧| jj游戏的235| 稠州游戏大厅下载| 黑鲨游戏手机| 老虎机243线怎么押注| 彩票投注工具| 远博娱乐彩票登录| s8比赛投注| 彩39彩票官方网站| 杭州边锋游戏下载| 常州游戏茶苑四副升级| 游戏茶苑| 手机现金捕鱼游戏下载| 任天堂娱乐| 打鱼代理平台| 最新500万彩票官网| 什么游戏中心最安全| 温州游戏茶苑2009| 手游棋牌绑定支付宝的| 胜利彩票极速分分彩| 体育滚球投注| 波克棋牌最新完整版本| 玩炸金花app| 金誉彩票网| 日本篮球联赛| jj比赛官方下载苹果| 茶苑游戏中心| 彩票开奖结果500彩票| 新凤凰彩票平台| 电子老虎机游戏大全| 边锋游戏大厅下载2012| 联众世界大厅官方下载| 吉祥棋牌游戏大厅下载| 玖乐3.0下载| 258竞彩官网| 老式老虎机游戏手机版| 棋牌开发| 彩票论坛大全| 105彩票官网| 互娱彩票| 新天地棋牌游戏大厅| 天吉论坛彩票分析预测| 大奖888娱乐游戏| 大发体育娱乐城备用网| 棋牌游戏大全免费下载| 安卓游戏电脑版下载| 买滚球的大型网站| 边锋3.0游戏大厅手机版| 新天地彩票平台注册| 娱乐平台pt老虎机平台| 德扑圈安卓| 东森娱乐平台手机登录| 足球757定律| 联众游戏下载中心| 鹿鼎彩票登录网址| 博宝娱乐| 哪个棋牌游戏能提现金| 足球竞彩app排名| 中国游戏在线中心官网| 手机捕鱼送分可上下分| 168彩票官网ios登录| 娱乐棋牌最新| 体彩网上投注站| 澳客彩票网| 棋牌游戏赚钱提现金| 有什么网站可以买球| 中国象棋真人在线| 彩88彩票官网| 波克棋牌下载大厅| 欧亿官网登录| 中国游戏在线中心| 立博体育在线网开户| 波克城市下载中心| 安博电竞

Xinhua Headlines: Chinese Nobel laureate's team resolves artemisinin resistance in malaria treatment

Source: Xinhua| 2019-06-26 17:20:33|Editor: Yamei
Video PlayerClose
安博电竞 事实上,调整车厢温度、空调吹风方向等都是细节方面的变化,点滴之间,看似不起眼,却让乘客受益颇多,感受到来自地铁管理方面的人文关怀,这也是社会文明进步、治理完善的体现,亦让市民对城市产生更多好感。

Xinhua Headlines: Chinese Nobel laureate's team resolves artemisinin resistance in malaria treatment

Chinese Nobel laureate Tu Youyou receives an interview with Xinhua at home in Beijing, capital of China, June 12, 2019. (Xinhua/Zhou Ning)

BEIJING, June 17 (Xinhua) -- Chinese Nobel laureate Tu Youyou announced Monday that her team has proposed solutions to the problem of artemisinin resistance, providing new evidence that artemisinin is still "the best weapon" against malaria, the world's No. 1 insect-borne infectious disease.

As the winner of the 2015 Nobel Prize for the discovery of artemisinin, Tu said that the drug resistance has remained a big challenge to fighting malaria.

Tu's team has been devoted to the study of the resistant mechanism since 2015 and discovered that partial artemisinin resistance is actually a delay in the clearance of malaria parasites from the bloodstream following treatment with combination therapy.

The 89-year-old scientist explained that plasmodia can enter a state of dormancy during the three-day Artemisinin Combination Treatment (ACT), while they also develop a resistance to partner drugs. But if the treatment period is extended to five to seven days and the partner drugs are replaced, the artemisinin resistance can be solved and plasmodia can be killed.

A paper on the study was published on the April issue of the New England Journal of Medicine (NEJM).

Pedro L. Alonso, director of the Global Malaria Programme of the World Health Organization (WHO), said the article published by Tu and her colleagues on NEJM, a top peer-reviewed journal, has demonstrated the excellence of her research ability. Billions of malaria cases have been treated through artemisinin-based combination therapies.

Artemisinin and its derivatives are known for their ability to swiftly reduce the number of parasites in the blood of patients with malaria and have saved millions of lives worldwide. WHO recommends ACTs as the first and second line treatment for malaria, which inflicts over 400,000 deaths every year worldwide.

The artemisinin resistance was formerly verified in the Greater Mekong river basins.

Tu said that treatment failures with ACTs are often directly attributed to the partner drug, which can be addressed by replacing the partner drug. For example, mefloquine plus artesunate can be switched to DHA with piperaquine if the former fails to deliver positive results.

Artemisinin substances are extracted from Qinghao, a kind of Chinese medicinal herb which has been used for more than 2,000 years in China for treating infectious diseases.

Since 2017, no malaria cases have been reported in China, indicating that the epidemic has been eradicated in the country. China has continued to carry out research on malaria control and prevention and develop artemisinin-based antimalarial drugs for the fight against the disease globally.

"Global malaria control is in line with the thrust of the Chinese government's initiative to build a community with a shared future for humanity," said Alonso. "The antimalarial research work carried out by Tu Youyou's team is groundbreaking, outstanding and immeasurable."

During the past three years of research, Tu's team has found that Artemisinins are also highly effective in treating Lupus Erythematous. Collaborating with 15 institutes nationwide, her team started clinical trials of the treatment in May 2018.

So far, 14 out of 500 applied domestic and foreign volunteer patients have been treated with the therapy. No unanticipated negative effects occurred. The three-phase trials will continue with an appraisal for China's official approval of the therapy to be expected around 2026.

Tu's Artemisinins-based research has helped draw more international attention to Traditional Chinese Medicine (TCM). Oxford University has invited Tu to add a chapter to the Oxford Medical Textbook (6th Edition).

The 6,000-word chapter entitled "Traditional Medicine Exemplified by Traditional Chinese Medicine" has been finalized. It is divided into four parts, explaining TCM, Artemisinin and other TCM's discovery history, their mechanisms and clinical applications. In April, Oxford University Press, the publisher, began proofreading the book.

Professor Timothy M. Cox, the editor of the Oxford Textbook of Medicine, said Tu Youyou's team has accomplished the work of integrating traditional Chinese and Western medicine. The chapter on TCM is important and in-depth so the world medical community can have a deep understanding of TCM.

Currently, the main challenge of TCM lies in the differences of evidence-based medicine, prohibiting TCM drugs including Artemisinins to enter the world's mainstream pharmaceutical markets. "All scientific research must be supported by solid data, evidence and well-designed protocols in order to comply with international medical standards and be accepted by the international community," said Alonso.

Although Chinese antimalarial drugs are highly effective and popular in African countries, the WHO spends a significant amount of its annual government procurement antimalarial funding mainly on foreign rather than Chinese pharmaceutical companies.

Xie Zheng, a technical officer of the WHO, said the production lines of Chinese pharmaceutical enterprises do not meet the WHO GMP technical standards and are difficult to obtain pre-qualification. They can only commission foreign pharmaceutical enterprises that meet the standards or go abroad in the way of government procurement.

China has made it a national strategy to encourage evidence-based medicine research and GMP standard construction so pharmaceutical enterprises can speed up the transformation of their production lines to obtain WHO certification and approval, said Liao Fulong, a senior researcher with Tu's team.

(Video reporters: Wang Junlu, Zhou Ning, Luo Guojun, Gai Boming; Video editor: Liu Xiaorui)

   1 2 Next  

KEY WORDS:
EXPLORE XINHUANET
010020070750000000000000011103261381506051
打麻将开挂 500彩票双色球杀号 捕鱼兑换现金送金币 668彩票网投 奇迹彩票网
联众棋牌游戏围棋 正规网络老虎机平台 下载银河玖乐 联众单机斗地主安卓版 买彩票的篮球APP 北京pc蛋蛋开奖网站 365福利彩票开奖 捕鱼平台排行榜2015手机版